Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17919
Full metadata record
DC FieldValueLanguage
dc.contributor.authorElander, N O-
dc.contributor.authorAughton, K-
dc.contributor.authorGhaneh, P-
dc.contributor.authorNeoptolemos, J P-
dc.contributor.authorPalmer, D H-
dc.contributor.authorCox, T F-
dc.contributor.authorCampbell, F-
dc.contributor.authorCostello, E-
dc.contributor.authorHalloran, C M-
dc.contributor.authorMackey, J R-
dc.contributor.authorScarfe, A G-
dc.contributor.authorValle, J W-
dc.contributor.authorMcDonald, A C-
dc.contributor.authorCarter, R-
dc.contributor.authorTebbutt, Niall C-
dc.contributor.authorGoldstein, D-
dc.contributor.authorShannon, J-
dc.contributor.authorDervenis, C-
dc.contributor.authorGlimelius, B-
dc.contributor.authorDeakin, M-
dc.contributor.authorCharnley, R M-
dc.contributor.authorAnthoney, Alan-
dc.contributor.authorLerch, M M-
dc.contributor.authorMayerle, J-
dc.contributor.authorOláh, A-
dc.contributor.authorBüchler, M W-
dc.contributor.authorGreenhalf, W-
dc.date2018-03-08-
dc.date.accessioned2018-06-21T05:28:39Z-
dc.date.available2018-06-21T05:28:39Z-
dc.date.issued2018-04-
dc.identifier.citationBritish Journal of Cancer 2018; 118(7): 947-954-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17919-
dc.description.abstractDihydropyrimidine dehydrogenase (DPD) tumour expression may provide added value to human equilibrative nucleoside transporter-1 (hENT1) tumour expression in predicting survival following pyrimidine-based adjuvant chemotherapy. DPD and hENT1 immunohistochemistry and scoring was completed on tumour cores from 238 patients with pancreatic cancer in the ESPAC-3(v2) trial, randomised to either postoperative gemcitabine or 5-fluorouracil/folinic acid (5FU/FA). DPD tumour expression was associated with reduced overall survival (hazard ratio, HR = 1.73 [95% confidence interval, CI = 1.21-2.49], p = 0.003). This was significant in the 5FU/FA arm (HR = 2.07 [95% CI = 1.22-3.53], p = 0.007), but not in the gemcitabine arm (HR = 1.47 [0.91-3.37], p = 0.119). High hENT1 tumour expression was associated with increased survival in gemcitabine treated (HR = 0.56 [0.38-0.82], p = 0.003) but not in 5FU/FA treated patients (HR = 1.19 [0.80-1.78], p = 0.390). In patients with low hENT1 tumour expression, high DPD tumour expression was associated with a worse median [95% CI] survival in the 5FU/FA arm (9.7 [5.3-30.4] vs 29.2 [19.5-41.9] months, p = 0.002) but not in the gemcitabine arm (14.0 [9.1-15.7] vs. 18.0 [7.6-15.3] months, p = 1.000). The interaction of treatment arm and DPD expression was not significant (p = 0.303), but the interaction of treatment arm and hENT1 expression was (p = 0.009). DPD tumour expression was a negative prognostic biomarker. Together with tumour expression of hENT1, DPD tumour expression defined patient subgroups that might benefit from either postoperative 5FU/FA or gemcitabine.-
dc.language.isoeng-
dc.titleExpression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.-
dc.typeJournal Article-
dc.identifier.journaltitleBritish Journal of Cancer-
dc.identifier.affiliationFrom the Cancer Research U.K. Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, UK-
dc.identifier.affiliationCross Cancer Institute and University of Alberta, Alberta, Canada-
dc.identifier.affiliationUniversity of Manchester/The Christie NHS Foundation Trust, Manchester, UK-
dc.identifier.affiliationThe Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK-
dc.identifier.affiliationGlasgow Royal Infirmary, Glasgow, Scotland, UK-
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationPrince of Wales hospital and Clinical School University of New South Wales, New South Wales, Australia-
dc.identifier.affiliationNepean Cancer Centre and University of Sydney, Sydney, Australia-
dc.identifier.affiliationThe Agia Olga Hospital, Athens, Greece-
dc.identifier.affiliationDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden-
dc.identifier.affiliationUniversity Hospital, North Staffordshire, UK-
dc.identifier.affiliationFreeman Hospital, Newcastle upon Tyne, UK-
dc.identifier.affiliationSt James's University Hospital, Leeds, UK-
dc.identifier.affiliationDepartment of Medicine A, University Medicine Greifswald, Greifswald, Germany-
dc.identifier.affiliationDepartment of Medicine II, University Hospital of the Ludwig-Maximilians-University, Munich, Germany-
dc.identifier.affiliationThe Petz Aladar Hospital, Gyor, Hungar-
dc.identifier.affiliationThe Department of Surgery, University of Heidelberg, Heidelberg, Germany-
dc.identifier.doi10.1038/s41416-018-0004-2-
dc.identifier.pubmedid29515256-
dc.type.austinJournal Article-
local.name.researcherTebbutt, Niall C
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Jun 21, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.